---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-26-043659"
form_type: "8-K"
ticker: "LUCD"
cik: "0001799011"
company_name: "Lucid Diagnostics Inc."
filed_at: "2026-09-22T13:06:43+00:00"
generated_at: "2026-09-22T13:08:31.526212+00:00"
event_type: "regulatory"
sentiment: "positive"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Lucid advances EsoGuard/EsoCheck Medicare coding, payment backing from CMS, AMA, CDC

## Summary
- CMS Advisory Panel recommends keeping EsoGuard's original gapfill payment basis (PLA code 0114U); final determinations due in November.
- AMA CPT Editorial Panel approves new Category III CPT code for non-endoscopic esophageal cell collection with EsoCheck.
- CDC/NCHS ICD-10 committee favorably receives proposed code R85.83 for positive EsoGuard results.
- Texas lab will begin submitting Medicare claims under 0114U this month; California lab to follow once revised LCD is effective.

## SEC filing metadata
- accession: 0001493152-26-043659
- form_type: 8-K
- ticker: LUCD
- cik: 0001799011
- company_name: Lucid Diagnostics Inc.
- filed_at: 2026-09-22T13:06:43+00:00
- event_type: regulatory
- sentiment: positive
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1799011/000149315226043659/0001493152-26-043659-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1799011/000149315226043659/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-26-043659
- JSON: https://secwatch.observer/filing/0001493152-26-043659.json
- Plain text: https://secwatch.observer/filing/0001493152-26-043659.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.